Morgan Stanley maintains Ascendis Pharma at Overweight; cuts price target
Morgan Stanley maintained Ascendis Pharma at Overweight and cut its price target to $273.00 per share from $275.00,
Ratings actions GMT) Ascendis Pharma Price Target Cut to $273.00/Share From $275.00 by Morgan StanleyRatings actions